IRIS - Res&Arch Institutional Research Information System - Research & Archive

CRINO', Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.645
EU - Europa 3.147
AS - Asia 3.102
SA - Sud America 581
Continente sconosciuto - Info sul continente non disponibili 289
AF - Africa 109
OC - Oceania 1
Totale 11.874
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.528
SG - Singapore 1.448
IE - Irlanda 598
RU - Federazione Russa 476
IT - Italia 459
BR - Brasile 455
CN - Cina 450
SE - Svezia 394
VN - Vietnam 385
HK - Hong Kong 336
UA - Ucraina 274
FR - Francia 226
DE - Germania 216
FI - Finlandia 197
GB - Regno Unito 104
KR - Corea 98
BD - Bangladesh 96
IN - India 67
CA - Canada 56
AR - Argentina 53
PL - Polonia 39
ZA - Sudafrica 32
MX - Messico 31
AT - Austria 30
TR - Turchia 30
IQ - Iraq 28
CH - Svizzera 25
JP - Giappone 23
ID - Indonesia 21
NL - Olanda 20
UZ - Uzbekistan 19
PK - Pakistan 16
EC - Ecuador 15
VE - Venezuela 15
ES - Italia 14
MA - Marocco 14
CO - Colombia 13
RO - Romania 13
CL - Cile 11
PH - Filippine 10
TN - Tunisia 10
BE - Belgio 9
CZ - Repubblica Ceca 9
GR - Grecia 9
KE - Kenya 9
LB - Libano 9
SA - Arabia Saudita 9
HR - Croazia 8
PY - Paraguay 8
SN - Senegal 8
EG - Egitto 7
JM - Giamaica 7
LT - Lituania 7
JO - Giordania 6
MY - Malesia 6
OM - Oman 6
BG - Bulgaria 5
BO - Bolivia 5
CR - Costa Rica 4
DZ - Algeria 4
ET - Etiopia 4
GT - Guatemala 4
IL - Israele 4
KZ - Kazakistan 4
NP - Nepal 4
PS - Palestinian Territory 4
TH - Thailandia 4
AO - Angola 3
AZ - Azerbaigian 3
BH - Bahrain 3
UY - Uruguay 3
AL - Albania 2
DO - Repubblica Dominicana 2
GA - Gabon 2
HN - Honduras 2
HU - Ungheria 2
IR - Iran 2
LV - Lettonia 2
ML - Mali 2
MU - Mauritius 2
NG - Nigeria 2
NI - Nicaragua 2
PA - Panama 2
PE - Perù 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
CD - Congo 1
CM - Camerun 1
DK - Danimarca 1
GE - Georgia 1
Totale 11.567
Salva come PNG Salva come JPEG
Città #
Singapore 994
Chandler 630
Dublin 598
San Jose 487
San Mateo 345
Hong Kong 334
Ashburn 240
Boardman 225
Santa Clara 199
Dong Ket 169
Andover 146
Medford 145
Princeton 143
Jacksonville 135
Moscow 132
Perugia 132
Altamura 129
Lauterbourg 125
Lawrence 123
Beijing 121
Ann Arbor 107
Wilmington 99
Seoul 98
Munich 83
Ho Chi Minh City 70
Los Angeles 64
New York 60
Hanoi 52
São Paulo 51
Saint Petersburg 45
Helsinki 39
The Dalles 36
Piscataway 35
Norwalk 31
Chicago 28
San Paolo di Civitate 28
Brooklyn 26
Warsaw 23
Frankfurt am Main 22
Tokyo 22
Des Moines 21
Rio de Janeiro 19
Turku 19
Johannesburg 18
Mexico City 16
Montreal 16
Nuremberg 16
Orem 16
Redwood City 16
Boston 15
Denver 15
Falls Church 14
London 14
Woodbridge 14
Dhaka 13
San Francisco 13
Baghdad 12
Bucharest 12
Chennai 12
Curitiba 12
Da Nang 12
Guangzhou 12
Poplar 12
Houston 11
Lausanne 11
Phoenix 11
Tashkent 11
Toronto 11
Vienna 11
Dallas 10
Shanghai 10
Brussels 9
Dearborn 9
Manchester 9
Rome 9
Stockholm 9
Atlanta 8
Dakar 8
Den Haag 8
Falkenstein 8
Istanbul 8
Nairobi 8
Osijek 8
Santo André 8
Tianjin 8
Auburn Hills 7
Biên Hòa 7
Cape Town 7
Haiphong 7
Santiago 7
Amsterdam 6
Belo Horizonte 6
Buenos Aires 6
Caracas 6
Goiânia 6
Guayaquil 6
Lahore 6
Lappeenranta 6
Milan 6
Mumbai 6
Totale 7.208
Salva come PNG Salva come JPEG
Nome #
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study 146
Afatinib In Egfr Mutant Non-small-cell Lung Cancer Patients With Acquired Resistance To Reversible Egfr-tkis 132
Prognostic Role of Erbb Family Receptors, Myc and Mitogen-activated Protein Kinase (mapk) In Patients With Early-stage Non Small-cell Lung Cancer 131
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 130
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 128
Significato prognostico dell’espressione immunoistochimica di Insulin like growth facor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 124
P-126 * PROGNOSTIC SIGNIFICANCE OF MYC AND HUMAN TELOMERASE GENE AMPLIFICATION IN SURGICALLY TREATED EARLY STAGE NON-SMALL CELL LUNG CANCER 122
A machine learning approach applied to Reverse Phase Protein Microarray data for pathways activation mapping of KRAS wild type and mutated adenocarcinomas of the lung 120
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer 119
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease 119
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 119
Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids 116
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. 115
MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non-small Cell Lung Cancer 114
Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. 112
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer 112
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 112
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer 111
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 110
A Hybrid Model of Nucleotide Excision Repair in Neoplastic diseases and in vitro Experiments 107
Combined chemotherapeutic and radiotherapeutic treatment of limited pulmonary microcytoma 107
Acute myeloblastic leukemia after adjuvant chemo¬therapy with melphalan in breast cancer. Case report with cytogenetic analysis. 106
Phase II study of weekly paclitaxel and trastuzumab in anthracycline and taxane pretreated patients with HER2 overexpressing metatastatic breast cancer 106
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment 106
Non-coding RNAs in lung cancer 105
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non-Small Cell Lung Cancer Patients 104
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors 103
An approach for optimally extending mathematical models of signaling networks using omics data 103
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort 101
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 101
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 101
A prospective study on survival in cancer patients with and without venous thromboembolism. 101
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 100
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients Results of the First Italian External Quality Assurance Scheme 98
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free servival in resected non-small-cell lung cancer patients. 96
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients 96
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 96
Carcinomi mammari "triple negative": studio dei fattori prognostici e predittivi. 95
Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. 95
Espressione dei recettori HER nei carcinomi non a piccole cellule del polmone 94
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 94
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology 93
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. 93
Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition 93
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 93
Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). 92
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 92
Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment 91
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 91
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection? 91
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 91
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 90
High coexpression of both insulin-like growth factor receptor 1 (igfr-1) and epidermal growth factor receptor (egfr) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients 89
PD-L1 quantification across tumor types using the reverse phase protein microarray: Implications for precision medicine 89
EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. 88
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy 88
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. 86
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 86
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. 85
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390) 85
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 84
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 84
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology (vol 30, pg 142, 2012) 83
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors 83
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 83
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 83
Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors. 82
Carcinomi mammari “triple negative”: studio dei fattori prognostici e predittivi 82
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 82
Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study 81
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. 79
Carcinomi mammari “tripli negativi”: significato biologico e prognostico dell’espressione di ERCC1. 78
Microinvasive breast cancer: clinical pathological characteristics and treatment. Experience from two institutions 78
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer A Phase-II Study 78
Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer. 78
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology 78
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 78
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 77
Systems biology in personalized medicine in oncology: A case study in non-small cell lung cancer 77
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 77
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 77
ERCC1 expression in triple negative breast carcinoma: the paradox revisited. 75
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype 75
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study 75
Significato prognostico dell'espressione immunoistochimica di insulin like growth factor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 74
First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer 74
Antigen-Presenting Signaling Events in the Tumor Ecology Associate with Response to Anti-PD-1 Treatment in Lung Cancer 73
Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors 73
Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop 73
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases 73
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 71
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 71
Italian Multicenter Phase III Randomized Study of Cisplatin-Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial 70
Perspectives on salvage therapy for non-small-cell lung cancer 69
Effect of genetic polymorphisms (GP) on toxicity and survival in early breast cancer (EBC) patients (PTS) treated with adjuvant chemotherapy (CT) 68
Emerging drugs for small cell lung cancer - an update 68
Mir-99a/let7c/mir-125b Signature To Predict Sensitivity To Anti-egfr Monoclonal Antibodies In Metastatic Colorectal Cancer (mcrc) 68
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. 67
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. 66
INSULIN-LIKE GROWTH FACTOR RECEPTOR 1 (IGF1R) AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION AND EXPRESSION IN SURGICALLY RESECTED NSCLC 65
Totale 9.243
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.997
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.123 0 237 12 75 19 11 7 446 14 12 119 171
2022/20232.061 149 394 16 180 157 206 0 96 772 1 69 21
2023/2024630 44 75 51 16 6 1 122 7 47 29 112 120
2024/20251.735 43 168 100 47 270 48 32 122 351 114 236 204
2025/20264.150 296 316 227 551 511 352 719 236 396 324 152 70
2026/2027166 76 90 0 0 0 0 0 0 0 0 0 0
Totale 11.874